Seroatlas · Human Serome Atlas

BLMH

Bleomycin hydrolase

Also known as: BH, BLMH_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q13867
Gene
BLMH
Ensembl
ENSG00000108578
Chromosome
17
Canonical length
455 aa
Protein class
Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins
Subcellular location
Nucleoplasm,Nuclear bodies,Cytosol
Quaternary structure
Homohexamer

OverviewNCBI Gene

Bleomycin hydrolase (BMH) is a cytoplasmic cysteine peptidase that is highly conserved through evolution; however, the only known activity of the enzyme is metabolic inactivation of the glycopeptide bleomycin (BLM), an essential component of combination chemotherapy regimens for cancer. The protein contains the signature active site residues of the cysteine protease papain superfamily. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

455 residues, UniProt reviewed canonical sequence.

>Q13867|BLMH
     1  MSSSGLNSEK VAALIQKLNS DPQFVLAQNV GTTHDLLDIC LKRATVQRAQ HVFQHAVPQE
    61  GKPITNQKSS GRCWIFSCLN VMRLPFMKKL NIEEFEFSQS YLFFWDKVER CYFFLSAFVD
   121  TAQRKEPEDG RLVQFLLMNP ANDGGQWDML VNIVEKYGVI PKKCFPESYT TEATRRMNDI
   181  LNHKMREFCI RLRNLVHSGA TKGEISATQD VMMEEIFRVV CICLGNPPET FTWEYRDKDK
   241  NYQKIGPITP LEFYREHVKP LFNMEDKICL VNDPRPQHKY NKLYTVEYLS NMVGGRKTLY
   301  NNQPIDFLKK MVAASIKDGE AVWFGCDVGK HFNSKLGLSD MNLYDHELVF GVSLKNMNKA
   361  ERLTFGESLM THAMTFTAVS EKDDQDGAFT KWRVENSWGE DHGHKGYLCM TDEWFSEYVY
   421  EVVVDRKHVP EEVLAVLEQE PIILPAWDPM GALAE

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BLMH can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.24
Highest tissue expression
128 nTPM

Expression across tissuesHPA

Tissue

  • skin: 128 nTPM
  • thymus: 34 nTPM
  • skeletal muscle: 28 nTPM
  • esophagus: 28 nTPM
  • pancreas: 26 nTPM
  • placenta: 26 nTPM

Single-cell type

  • cytotrophoblasts: 72 nCPM
  • esophageal basal cells: 54 nCPM
  • erythrocyte progenitors: 53 nCPM
  • undifferentiated spermatogonia: 53 nCPM
  • megakaryocyte progenitors: 53 nCPM
  • migrating cytotrophoblasts: 50 nCPM

Immune cell

  • MAIT T-cell: 25 nTPM
  • memory CD8 T-cell: 20 nTPM
  • T-reg: 20 nTPM
  • memory CD4 T-cell: 18 nTPM
  • naive CD8 T-cell: 18 nTPM
  • naive CD4 T-cell: 17 nTPM

Brain region

  • white matter: 19 nTPM
  • medulla oblongata: 18 nTPM
  • cerebellum: 18 nTPM
  • hypothalamus: 17 nTPM
  • basal ganglia: 16 nTPM
  • pons: 16 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.48
gnomAD pLI
0.13
gnomAD missense Z
1.63
DepMap mean gene effect
-0.01
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of BLMH in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BLMH as an antibody target. Whether an autoantibody or antibody against BLMH could matter depends on whether native BLMH is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BLMH is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label BLMH as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/BLMH. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...